CAR T-cell immunotherapy treating T-ALL: Challenges and opportunities

A Ren, X Tong, N Xu, T Zhang, F Zhou, H Zhu - Vaccines, 2023 - mdpi.com
T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically
aggressive hematological malignancy with high rates of disease relapse and a poor …

Emerging role of T-cell receptor constant β chain-1 (TRBC1) expression in the flow cytometric diagnosis of T-cell malignancies

P Horna, M Shi, H Olteanu, U Johansson - International journal of …, 2021 - mdpi.com
T-cell clonality testing is integral to the diagnostic work-up of T-cell malignancies; however,
current methods lack specificity and sensitivity, which can make the diagnostic process …

A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?

AE Andrea, A Chiron, G Sarrabayrouse… - Frontiers in …, 2024 - frontiersin.org
In recent years, following the groundbreaking achievements of chimeric antigen receptor
(CAR) T cell therapy in hematological cancers, and advancements in cell engineering …

Integration of T‐cell clonality screening using TRBC‐1 in lymphoma suspect samples by flow cytometry

F Castillo, C Morales, B Spralja… - Cytometry Part B …, 2024 - Wiley Online Library
Background The diagnosis of T‐cell non‐Hodgkin lymphomas (NHL) is challenging. The
development of a monoclonal antibody specific for T‐cell receptor β constant region 1 …

“Clone-specific” antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers

D Jungherz, P Lückemeier, M Herling - Signal Transduction and …, 2024 - nature.com
In a recent study published in Nature, Nichakawade et al. provided proof-of-principle data on
innovative strategies to target and eliminate cancerous T-cells while sparing healthy T …